2 results
Approved WMORecruiting
* To demonstrate the efficacy of VLA15 in preventing confirmed Lyme disease in the Lyme disease season after completion of the primary series vaccination and booster dose.* To describe the safety profile of VLA15 as measured by the percentage of…
Approved WMORecruiting
TEMPO will directly compare i) conventional 2-step reduction with ii) gradual tapering in patients with remitted MDD who use either the antidepressant paroxetine (PAR) or venlafaxine (VLX). We will evaluate the number of patients that can…